Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sarah Gheuens Sells 2,940 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 2,940 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $34.71, for a total transaction of $102,047.40. Following the completion of the transaction, the insider directly owned 80,277 shares in the company, valued at $2,786,414.67. This represents a 3.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Agios Pharmaceuticals Trading Down 1.1%

Shares of Agios Pharmaceuticals stock opened at $34.80 on Tuesday. The firm’s 50-day moving average price is $29.00 and its 200 day moving average price is $32.12. The firm has a market capitalization of $2.04 billion, a PE ratio of -4.89 and a beta of 0.79. Agios Pharmaceuticals, Inc. has a twelve month low of $22.24 and a twelve month high of $46.00.

Institutional Trading of Agios Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Bellevue Group AG raised its holdings in Agios Pharmaceuticals by 3.5% in the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock valued at $149,110,000 after buying an additional 124,586 shares during the period. State Street Corp lifted its position in Agios Pharmaceuticals by 37.4% in the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock valued at $84,604,000 after buying an additional 845,433 shares during the last quarter. Erste Asset Management GmbH lifted its position in Agios Pharmaceuticals by 1.4% in the fourth quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock valued at $76,343,000 after buying an additional 40,000 shares during the last quarter. Wellington Management Group LLP lifted its position in Agios Pharmaceuticals by 485.5% in the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after buying an additional 2,049,287 shares during the last quarter. Finally, Commodore Capital LP lifted its position in Agios Pharmaceuticals by 0.6% in the third quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock valued at $93,859,000 after buying an additional 13,287 shares during the last quarter.

Key Stories Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: JPMorgan raised its price target on AGIO from $31 to $36 (maintaining a “neutral” rating), signaling modest analyst upside and providing some support for the share price. Article Link
• Neutral Sentiment: Agios scheduled its Q1 2026 earnings conference call and webcast for April 29, 2026 — a standard corporate update that can trigger short-term moves around results but is informational until the release. Press Release
• Neutral Sentiment: Insider sale — Tsveta Milanova sold 3,262 shares at ~$34.71 under a pre-arranged Rule 10b5-1 plan to cover tax withholding from equity vesting; trade reduces her holdings ~6.5% but was routine and pre-planned. SEC Filing
• Neutral Sentiment: Insider sale — CFO Cecilia Jones sold 3,141 shares at ~$34.71 via a Rule 10b5-1 plan to cover taxes on vested awards; holding reduced ~5.4%. Investors typically view such planned tax-related sales as neutral. SEC Filing
• Neutral Sentiment: Insider sale — Sarah Gheuens sold 2,940 shares at ~$34.71 under a pre-arranged plan to cover tax withholding; position decreased ~3.5%. SEC Filing
• Neutral Sentiment: Insider sale — James William Burns sold 3,280 shares at ~$34.71 via a Rule 10b5-1 plan to cover tax obligations; holdings down ~6.2%. SEC Filing

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Bank of America raised their price objective on Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. Truist Financial raised their target price on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, December 24th. Wall Street Zen raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. HC Wainwright raised their target price on shares of Agios Pharmaceuticals from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, February 12th. Finally, Leerink Partners raised their target price on shares of Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, December 26th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $42.67.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.